SkinBioTherapeutics PLC SkinBiotix platform passes external toxicity tests (9751V)
09 November 2017 - 6:00PM
UK Regulatory
TIDMSBTX
RNS Number : 9751V
SkinBioTherapeutics PLC
09 November 2017
SkinBioTherapeutics plc
SkinBiotix(R) platform passes additional external toxicity
tests
Scientific progress on track
Manchester, UK - 9 November 2017 - SkinBioTherapeutics plc (AIM:
SBTX, the "Company"), a life science company focused on skin
health, has passed two additional and final third party cellular
toxicity tests for its SkinBiotix(R) technology.
The in vitro tests, for photo-toxicity (sensitivity to sunlight)
and ocular toxicity (effect on eye cells), follow on from the
recent first stage cytotoxicity tests, as announced on 3 October
2017
The studies were again conducted by Charles River Laboratories,
a Contract Research Organisation (CRO), in accordance with the OECD
Principles of Good Laboratory Practice.
In the photo-toxicity test, the testers were looking to
determine whether the SkinBiotix(R) technology would become toxic
to cells when exposed to UV and visible light. The results showed
that SkinBiotix(R) is non-phototoxic.
The second test, for ocular toxicity, was carried out to
determine whether SkinBiotix(R) is toxic to eye cells. This
involved measuring for two important components which are
predictive of irritation, corneal opacity (cloudiness) and
permeability (ability to let fluids pass through the eye). The
SkinBiotix(R) technology also passed this test.
SkinBioTherapeutics will continue developing the technology
towards the three applications in skin care, anti-infection and
skin repair.
Dr Catherine O'Neill, CEO of SkinBioTherapeutics, commented:
"Since announcing that the SkinBiotix platform passed the key
cytotoxicity test in October, we have been focussing on further
proving its efficacy.
"With this news today, the technology has passed the three
necessary toxicity tests showing that it can be safely applicable
across our three target markets.
"We are continuing formulation development and are confident
about starting our human studies in 2018."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
-Ends-
For more information, please contact:
SkinBioTherapeutics plc Tel: +44 (0) 161 468
Dr. Cath O'Neill, CEO 2760
Doug Quinn, CFO
Cairn Financial Advisers LLP Tel: +44 (0) 20 7213
Tony Rawlinson / Emma Earl / Richard 0880
Nash
Turner Pope Investments Tel: +44 (0) 20 3621
Ben Turner / James Pope 4120
Instinctif Partners Tel: +44 (0) 20 7457
Melanie Toyne-Sewell / Deborah Bell 2020
SkinBio@instinctif.com
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin
health. The Company's proprietary platform technology,
SkinBiotix(R), is based upon discoveries made by CEO Dr. Catherine
O'Neill and Professor Andrew McBain.
SkinBioTherapeutics' platform applies research discoveries made
on the activities of lysates derived from probiotic bacteria when
applied to the skin. The Company has shown that the SkinBiotix(R)
platform can improve the barrier effect of skin models, protect
skin models from infection and repair skin models. Proof of
principle studies have shown that the SkinBiotix(R) platform has
beneficial attributes applicable to each of these areas.
SkinBioTherapeutics received seed funding from the Tech Transfer
office of the University of Manchester for the discovery of
SkinBiotix(R). The platform was subsequently spun out of the
University of Manchester in March 2016 and was funded by OptiBiotix
(AIM: OPTI).
The Company joined AIM in April 2017 concurrent with raising
GBP4.5 million from a placing of new ordinary shares.
The Company is based in Manchester, UK. For more information,
visit www.skinbiotherapeutics.com.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their
research and drug development efforts. Its dedicated employees are
focused on providing clients with exactly what they need to improve
and expedite the discovery, early-stage development and safe
manufacture of new therapies for the patients who need them. To
learn more about Charles Rivers' unique portfolio and breadth of
services, visit www.criver.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAXFPEASXFFF
(END) Dow Jones Newswires
November 09, 2017 02:00 ET (07:00 GMT)
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Apr 2023 to Apr 2024